Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16620366 | 0.84 | ALDH1A1 (0.45) | MPOALDH1A1KDM4ELTA4HEPHX2 | |
| SCHEMBL29447706 | 0.73 | CYP11B1 (0.35) | SMN1; SMN2 | |
| SCHEMBL16620146 | 0.71 | ALDH1A1 (0.39) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL16620202 | 0.70 | ALDH1A1 (0.43) | ALDH1A1SMOL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL28067981 | 0.69 | MAPT (0.32) | — | |
| SCHEMBL20560054 | 0.68 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL20401326 | 0.64 | ACSS2 (0.39) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL29447613 | 0.64 | CYP11B1 (0.35) | — | |
| SCHEMBL12074315 | 0.64 | HDAC8 (0.36) | SMO | |
| SCHEMBL14895594 | 0.63 | PDPK1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3363800-A1 | HETEROCYCLIC INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9951078-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3052096-B1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9624228-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | KURA ONCOLOGY, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3052096-A1 | INHIBITORS OF ERK AND METHODS OF USE | Kura Oncology, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| CN-105636586-A | ERK inhibitors and methods of use | ARAXES PHARMA LLC | 2016-06-01 | — | — | CN | disclosed |
| WO-2015051341-A1 | INHIBITORS OF ERK AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301317-B2 | Inhibitors of ERK and methods of use | MAP3K1, MAP3K2, MAP3K6 | MPO 2956/4885ALDH1A1 2763/4885KDM4E 2463/4885 |
| US-20170226110-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | MPO 2956/4885ALDH1A1 2763/4885KDM4E 2463/4885 |
| US-20180237444-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | MPO 2956/4885ALDH1A1 2763/4885KDM4E 2463/4885 |
| US-20190292194-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | MPO 2956/4885ALDH1A1 2763/4885KDM4E 2463/4885 |
| US-20160237091-A1 | INHIBITORS OF ERK AND METHODS OF USE | MAP3K1, MAP3K2, MAP3K6 | MPO 2956/4885ALDH1A1 2763/4885KDM4E 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.